Tuveson DA - Search Results

1

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG. Chan IT, et al. Among authors: tuveson da. J Clin Invest. 2004 Feb;113(4):528-38. doi: 10.1172/JCI20476. J Clin Invest. 2004. PMID: 14966562 Free PMC article.

2

Technologically advanced cancer modeling in mice.

Tuveson DA, Jacks T. Tuveson DA, et al. Curr Opin Genet Dev. 2002 Feb;12(1):105-10. doi: 10.1016/s0959-437x(01)00272-6. Curr Opin Genet Dev. 2002. PMID: 11790563 Review.

3

Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.

Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch R, Jacks T. Shaw AT, et al. Among authors: tuveson da. Genes Dev. 2007 Mar 15;21(6):694-707. doi: 10.1101/gad.1526207. Genes Dev. 2007. PMID: 17369402 Free PMC article.

4

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.

Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Johnson L, et al. Among authors: tuveson da. Nature. 2001 Apr 26;410(6832):1111-6. doi: 10.1038/35074129. Nature. 2001. PMID: 11323676

5

Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways.

Zhang J, Liu Y, Beard C, Tuveson DA, Jaenisch R, Jacks TE, Lodish HF. Zhang J, et al. Among authors: tuveson da. Blood. 2007 Jun 15;109(12):5238-41. doi: 10.1182/blood-2006-09-047050. Epub 2007 Feb 22. Blood. 2007. PMID: 17317860 Free PMC article.

6

Modeling human lung cancer in mice: similarities and shortcomings.

Tuveson DA, Jacks T. Tuveson DA, et al. Oncogene. 1999 Sep 20;18(38):5318-24. doi: 10.1038/sj.onc.1203107. Oncogene. 1999. PMID: 10498884 Review.

7

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. Jackson EL, et al. Among authors: tuveson da. Genes Dev. 2001 Dec 15;15(24):3243-8. doi: 10.1101/gad.943001. Genes Dev. 2001. PMID: 11751630 Free PMC article.

8

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Olive KP, et al. Among authors: tuveson da. Cell. 2004 Dec 17;119(6):847-60. doi: 10.1016/j.cell.2004.11.004. Cell. 2004. PMID: 15607980 Free article.

9

Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Braun BS, et al. Among authors: tuveson da. Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602. doi: 10.1073/pnas.0307203101. Epub 2003 Dec 29. Proc Natl Acad Sci U S A. 2004. PMID: 14699048 Free PMC article.

10

The differential effects of mutant p53 alleles on advanced murine lung cancer.

Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. Jackson EL, et al. Among authors: tuveson da. Cancer Res. 2005 Nov 15;65(22):10280-8. doi: 10.1158/0008-5472.CAN-05-2193. Cancer Res. 2005. PMID: 16288016

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page